Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference Ready to Announce with Confidence?
King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL ® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.
Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be available for one-on-one investor meetings throughout the event.
"All investors are invited to join this event to learn more about Phio Pharmaceuticals and our continuing pursuit towards a cancer free future using our INTASYL technology," stated Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals. "Completion of treatment in the Phase 1b trial for PH-762 marks a significant step forward in advancing a promising treatment option for skin cancer."
Event Details are as follows:
3rd Annual DealFlow Discovery Conference
The Borgata Hotel, Casino & Spa
Atlantic City, NJ
January 28-29, 2026
Investors interested in scheduling a meeting with Phio Pharmaceuticals management team can register ( Investors - DealFlow Discovery Conference) to attend the conference at no cost.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL ® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The ongoing Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells, the potential for PH-762 to present a viable non-surgical alternative for skin cancer, expectations regarding timing of enrollment, the expectations that we have sufficient capital to complete the treatment phase of our ongoing Phase 1b clinical trial, and statements regarding our clinical strategy, development plans and timelines and other future events.
These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, results from our preclinical and clinical activities, our ability to execute on business strategies, the timing or likelihood of regulatory filings and approvals, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281484
Source: Phio Pharmaceuticals Corp.
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Phio Pharmaceuticals Corp. or all companies in the Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health industry.
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
2026-01-26 8:15 AM EST
Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial
2026-01-20 9:30 AM EST
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026
2026-01-15 8:45 AM EST
Dec 18, 2025
In 2025, more than 39,000 press releases distributed through Newsfile offer a clear lens into how public companies are communicating with the market. At this scale, individual announcements fade into the background, and what emerges instead are patterns . The language companies choose reveals how industries are evolving, where credibility is being built, and what investors are being asked to trust. Last year, this analysis focused on identifying the most common keywords by industry. This...
Economy, Business and Finance
Biotechnology
Chemicals
Pharmaceutical
Health
Hospital and Clinic
Biotechnology
Healthcare and Hospitals
Pharmaceuticals
Health